Back to Journals » Diabetes, Metabolic Syndrome and Obesity » Volume 12 » SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
Please verify you are not a robot.